Aminoglycosides are a powerful class of bactericidal antibiotics used primarily to treat severe infections caused by gram-negative aerobic bacilli. In the context of midwifery and obstetric care, these medications are rarely first-line choices for routine conditions due to their significant toxicity profile. However, they become critical lifelines when managing severe maternal sepsis, chorioamnionitis, or postpartum pelvic infections that fail to respond to safer broad-spectrum agents. Because they cross the placenta and can accumulate in fetal tissues, their use during pregnancy requires careful risk-benefit analysis by the clinical team. Midwives must understand both their potency against stubborn pathogens and the strict safety boundaries required for maternal and neonatal well-being.
These agents work through a direct bactericidal mechanism. Once inside the bacterial cell, they bind irreversibly to the 30S ribosomal subunit. This binding disrupts normal protein synthesis by causing the genetic code to be misread, leading to the production of faulty, non-functional proteins. Furthermore, they disrupt the bacterial cell membrane integrity. Their spectrum covers severe aerobic gram-negative bacilli such as Escherichia coli, Klebsiella, Proteus, and Pseudomonas species. They are frequently combined synergistically with a beta-lactam antibiotic, such as ampicillin, to treat severe enterococcal infections, because the beta-lactam weakens the cell wall and allows the aminoglycoside to enter the bacterium more easily.
In maternity and women's health wards, aminoglycosides are deployed against specific, high-risk bacterial invasions.
Aminoglycosides are poorly absorbed through the gastrointestinal tract, meaning they must be administered parenterally—usually via intravenous infusion or intramuscular injection—for systemic infections. They have a narrow therapeutic index, meaning the concentration required to treat an infection is very close to the concentration that causes toxicity. Once-daily dosing schedules have largely replaced older multiple-daily-dose regimens because they allow for higher peak drug concentrations to kill bacteria effectively while providing a washout period that reduces kidney accumulation and toxicity.
The use of aminoglycosides during pregnancy carries distinct hazards. The two major toxicities are nephrotoxicity (kidney damage) and ototoxicity (damage to the inner ear and auditory nerves). These drugs freely cross the placental barrier. Fetal exposure can lead to congenital ototoxicity, resulting in irreversible bilateral sensorineural hearing loss and vestibular damage in the newborn. Additionally, maternal fluid balance and renal clearance change dramatically during pregnancy, making standard dosing tricky and increasing the likelihood of unexpected drug accumulation if levels are not closely watched.
Safe administration of aminoglycosides requires routine laboratory monitoring of serum drug concentrations, known as therapeutic drug monitoring (TDM). Clinicians check both peak levels (to ensure the dose is high enough to kill bacteria) and trough levels (to ensure the drug has cleared enough to prevent kidney toxicity). Midwives and nurses must also track maternal urine output daily, as a sudden drop in output is an early sign of acute kidney injury. Patients should be instructed to report any new ringing in the ears, dizziness, or vertigo immediately, as these are hallmark symptoms of emerging ototoxicity.
Midwives managing patients on aminoglycosides bear heavy safety responsibilities. Before starting treatment, verify baseline kidney function tests, including serum creatinine and blood urea nitrogen. Ensure exact calculation of doses based on accurate maternal weight. During infusion, adhere strictly to hospital timing guidelines for drawing blood samples for drug assays. Educate the mother on reporting unusual sensory symptoms like dizziness or hearing changes. Finally, ensure prompt documentation of all administration times and fluid balance records to catch adverse signs before permanent damage occurs.